MRTX849

Target: This ligand targets KRAS G12C mutant protein in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for KRAS G12C mutant protein. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings KRAS G12C mutant protein into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Driven Degradation Studies: MRTX849 can be used as a recruiting ligand in PROTAC designs to drive selective degradation of its intended kinase target. By pairing MRTX849 with an E3 ligase-binding moiety, researchers can evaluate ternary complex formation, ubiquitination efficiency, and target protein loss across cell lines, enabling mechanistic dissection of degradation versus inhibition.

• Optimizing Linker Length and Chemistry: In PROTAC optimization workflows, MRTX849-based chimeras are valuable for systematically tuning linker length, rigidity, and attachment points. These variables can substantially affect spatial orientation, binding cooperativity, and degradation potency. Researchers can compare degradation kinetics and dose-response profiles to identify constructs that maximize target turnover while minimizing off-target degradation.

• Mapping Resistance and Escape Mechanisms: MRTX849-containing PROTACs support studies of resistance pathways by assessing how mutations, pathway rewiring, or altered proteasome/ubiquitin system activity impact degradation. Comparing degradation outcomes with kinase inhibition readouts helps distinguish whether resistance arises from impaired recruitment, reduced ternary complex stability, or disrupted ubiquitination and trafficking.

• Profiling Selectivity Across Proteomes: MRTX849-based PROTACs can be applied to evaluate target selectivity by measuring degradation breadth using proteomics or targeted immunoblot panels. This approach helps determine whether the chimeric construct preferentially eliminates the intended kinase while limiting degradation of related kinases or signaling proteins, informing rational refinement of ligand engagement and E3 ligase choice.

MRTX849 is a KRAS G12C target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of MRTX849 is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.